Skip to content
DataLookout
Menu

NCT07908329

Intradermal Influenza Vaccination

StatusRecruiting
PhaseEarly Phase 1
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in antibody titer concentration to vaccination-Blood
Timeframe: Day 0 and Day 28
Change in antibody titer concentration to vaccination-Skin
Timeframe: Day 0 and Day 28

Secondary (1)

Change in antibody titer concentration to vaccination

Arms and interventions

HealthyActive comparator

Healthy participants will receive either intramuscular or intradermal flu vaccination.

Cancer (Exploratory Arm)Other

Cancer patients about to undergo Immune Checkpoint Inhibitor (ICI) therapy will receive either intramuscular or intradermal flu vaccination.

Post acute infection syndrome (PAIS) (Exploratory Arm)Other

PAIS patients will receive either intramuscular or intradermal flu vaccination

Devices: MicronJet

Biologicals: Fluzone® Quadrivalent, Fluzone® High Dose Quadrivalent

Sites

1 site in 1 country

  • Church Street Research UnitNew Haven, Connecticut, United States